Elanco Animal Health (ELAN) Set to Post Earnings on Friday

Key Points

• Elanco is expected to report Q3 2026 results before the market opens Friday, November 6. Analysts project EPS of $0.2028 and revenue of $1.21 billion, compared with company guidance of $0.190–$0.220 EPS.
• The company beat expectations in its prior quarter, reporting $0.34 EPS versus the $0.27 consensus and $1.37 billion in revenue, up 10.2% year over year.
• Analyst sentiment is moderately bullish, with an average price target of $29.33 versus a recent share price of $23.25. However, ratings are mixed, including Jefferies’ downgrade to “hold” and a $24 price target.

Elanco Animal Health (NYSE:ELAN - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of $0.2028 per share and revenue of $1.21 billion for the quarter. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. Elanco Animal Health's revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.26 EPS. On average, analysts expect Elanco Animal Health to post $1.13 EPS for the current fiscal year and $1.28 EPS for the next fiscal year.

Elanco Animal Health Stock Up 2.6%

Shares of ELAN opened at $23.25 on Friday. The stock has a market capitalization of $11.61 billion, a PE ratio of -56.70, a P/E/G ratio of 2.01 and a beta of 1.70. Elanco Animal Health has a 1 year low of $19.40 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The company's 50-day simple moving average is $23.14 and its 200-day simple moving average is $23.82.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. UBS Group increased their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. KeyCorp restated an "overweight" rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Weiss Ratings raised Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, September 4th. Jefferies Financial Group cut Elanco Animal Health from a "buy" rating to a "hold" rating and reduced their price objective for the company from $31.00 to $24.00 in a research note on Tuesday, October 20th. Finally, The Goldman Sachs Group began coverage on Elanco Animal Health in a report on Friday, October 16th. They issued a "buy" rating and a $32.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has an average rating of "Moderate Buy" and an average price target of $29.33.

Insider Transactions at Elanco Animal Health

In other news, insider Shiv O'Neill bought 3,998 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the acquisition, the insider directly owned 87,832 shares in the company, valued at $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Harrington purchased 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average price of $21.82 per share, with a total value of $109,100.00. Following the purchase, the director directly owned 131,451 shares of the company's stock, valued at $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 63,198 shares of company stock valued at $1,473,109 over the last quarter. Insiders own 1.14% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company's products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.